Skip to main content
Clinical Trials/CTRI/2018/05/014023
CTRI/2018/05/014023
Completed
Phase 2

CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPAGHANA VATI AND TOTALA HIMA IN CHRONIC HEPATITIS B

Patanjali Ayurveda College0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: K739- Chronic hepatitis, unspecified
Sponsor
Patanjali Ayurveda College
Enrollment
50
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
February 18, 2019
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Patanjali Ayurveda College

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients irrespective of sex, religion, occupation and chronicity will be selected.
  • 2\. Patients with two times higher ALT levels than the upper limit of normal value will be selected.
  • 3\. Patients with symptoms and signs of hepatitis B, abnormal liver functions and diagnosed cases of Chronic Hepatitis B infection will be registered.

Exclusion Criteria

  • 1\. Patients aged \>65 years or \<18 years will be excluded.
  • 2\. Pregnant or lactating women will be excluded.
  • 3\. Patients who had hepatitis C or other hepatic viral infection, autoimmune hepatitis and drug\-induced hepatitis or alcoholic hepatitis will be excluded.
  • 4\. Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded.
  • 5\. Patients will be excluded having decompensated liver disease.
  • 6\. Patients with prolonged or a history of ascites, developed hepato\-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded.
  • 7\. Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials